| Dr Michele A Brother, MD | |
|
1600 E Broadway, Columbia, MO 65201-5844 | |
| (573) 815-8000 | |
| Not Available |
| Full Name | Dr Michele A Brother |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 28 Years |
| Location | 1600 E Broadway, Columbia, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033153598 | NPI | - | NPPES |
| 205162316 | Medicaid | MO | |
| P00314603 | Other | MO | RAILROAD MEDICARE |
| 431560263010 | Other | MO | TRICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 110932 (Missouri) | Primary |
| 208M00000X | Hospitalist | 110932 (Missouri) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Christian Hospital Northeast | Saint louis, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Physician Groups Lc | 3072421254 | 409 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
The Center for Global Health Policy's "Science Speaks" blog rounds up results presented at a late breaker session at last week's 2nd International Treatment as Prevention Workshop in Vancouver. The blog notes the session "offered some interesting insights relevant to HIV treatment scale up."
The quality of the tissue-implant interface is key to the success of implant integration. High-output benchtop screening can help developers in assessing the complex interplay between biomaterials and the body to better prepare for clinical trials, highlights a review in the journal Science and Technology of Advanced Materials.
Tragic miscarriages for a couple have led to a discovery with potentially broad implications for future disease treatments, according to a team of researchers at the University of North Carolina School of Medicine. They identified a previously undiscovered gene mutation underlying hydrops fetalis – a fatal condition to fetuses due to fluid buildup in the space between organs.
A University of British Columbia study shows that there are enough pharmacies situated throughout Ontario communities to absorb many closures without negatively affecting geographical accessibility for residents. The research suggests concerns that reducing generic pricing could result in pharmacy shortages are unfounded.
› Verified 7 days ago
| Entity Name | Hannibal Regional Healthcare System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003956095 PECOS PAC ID: 1254236300 Enrollment ID: O20031203000229 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
The Center for Global Health Policy's "Science Speaks" blog rounds up results presented at a late breaker session at last week's 2nd International Treatment as Prevention Workshop in Vancouver. The blog notes the session "offered some interesting insights relevant to HIV treatment scale up."
The quality of the tissue-implant interface is key to the success of implant integration. High-output benchtop screening can help developers in assessing the complex interplay between biomaterials and the body to better prepare for clinical trials, highlights a review in the journal Science and Technology of Advanced Materials.
Tragic miscarriages for a couple have led to a discovery with potentially broad implications for future disease treatments, according to a team of researchers at the University of North Carolina School of Medicine. They identified a previously undiscovered gene mutation underlying hydrops fetalis – a fatal condition to fetuses due to fluid buildup in the space between organs.
A University of British Columbia study shows that there are enough pharmacies situated throughout Ontario communities to absorb many closures without negatively affecting geographical accessibility for residents. The research suggests concerns that reducing generic pricing could result in pharmacy shortages are unfounded.
› Verified 7 days ago
| Entity Name | Physician Groups Lc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285664268 PECOS PAC ID: 3072421254 Enrollment ID: O20040220001157 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
The Center for Global Health Policy's "Science Speaks" blog rounds up results presented at a late breaker session at last week's 2nd International Treatment as Prevention Workshop in Vancouver. The blog notes the session "offered some interesting insights relevant to HIV treatment scale up."
The quality of the tissue-implant interface is key to the success of implant integration. High-output benchtop screening can help developers in assessing the complex interplay between biomaterials and the body to better prepare for clinical trials, highlights a review in the journal Science and Technology of Advanced Materials.
Tragic miscarriages for a couple have led to a discovery with potentially broad implications for future disease treatments, according to a team of researchers at the University of North Carolina School of Medicine. They identified a previously undiscovered gene mutation underlying hydrops fetalis – a fatal condition to fetuses due to fluid buildup in the space between organs.
A University of British Columbia study shows that there are enough pharmacies situated throughout Ontario communities to absorb many closures without negatively affecting geographical accessibility for residents. The research suggests concerns that reducing generic pricing could result in pharmacy shortages are unfounded.
› Verified 7 days ago
| Entity Name | Cole Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144578659 PECOS PAC ID: 0648420810 Enrollment ID: O20121024000296 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
The Center for Global Health Policy's "Science Speaks" blog rounds up results presented at a late breaker session at last week's 2nd International Treatment as Prevention Workshop in Vancouver. The blog notes the session "offered some interesting insights relevant to HIV treatment scale up."
The quality of the tissue-implant interface is key to the success of implant integration. High-output benchtop screening can help developers in assessing the complex interplay between biomaterials and the body to better prepare for clinical trials, highlights a review in the journal Science and Technology of Advanced Materials.
Tragic miscarriages for a couple have led to a discovery with potentially broad implications for future disease treatments, according to a team of researchers at the University of North Carolina School of Medicine. They identified a previously undiscovered gene mutation underlying hydrops fetalis – a fatal condition to fetuses due to fluid buildup in the space between organs.
A University of British Columbia study shows that there are enough pharmacies situated throughout Ontario communities to absorb many closures without negatively affecting geographical accessibility for residents. The research suggests concerns that reducing generic pricing could result in pharmacy shortages are unfounded.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michele A Brother, MD 1600 E Broadway, Columbia, MO 65201-5844 Ph: (573) 815-8000 | Dr Michele A Brother, MD 1600 E Broadway, Columbia, MO 65201-5844 Ph: (573) 815-8000 |
News Archive
Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.
The Center for Global Health Policy's "Science Speaks" blog rounds up results presented at a late breaker session at last week's 2nd International Treatment as Prevention Workshop in Vancouver. The blog notes the session "offered some interesting insights relevant to HIV treatment scale up."
The quality of the tissue-implant interface is key to the success of implant integration. High-output benchtop screening can help developers in assessing the complex interplay between biomaterials and the body to better prepare for clinical trials, highlights a review in the journal Science and Technology of Advanced Materials.
Tragic miscarriages for a couple have led to a discovery with potentially broad implications for future disease treatments, according to a team of researchers at the University of North Carolina School of Medicine. They identified a previously undiscovered gene mutation underlying hydrops fetalis – a fatal condition to fetuses due to fluid buildup in the space between organs.
A University of British Columbia study shows that there are enough pharmacies situated throughout Ontario communities to absorb many closures without negatively affecting geographical accessibility for residents. The research suggests concerns that reducing generic pricing could result in pharmacy shortages are unfounded.
› Verified 7 days ago
Dr. Rahul Jain, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Hospital Dr, Columbia, MO 65212 Phone: 573-884-2296 Fax: 573-884-7743 | |
Gregory Gaskey, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1 Hospital Dr, Columbia, MO 65212 Phone: 573-884-9066 Fax: 573-884-3037 | |
Christos N Papageorgiou, M.D., PHD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: One Hospital Drive, Columbia, MO 65212 Phone: 573-882-2100 Fax: 573-884-7822 | |
Jack Bragg, DO Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 101 S Fairview Road, Columbia, MO 65201 Phone: 573-884-7600 Fax: 573-884-8200 | |
Michelle Middleton Woodson, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 800 Hospital Dr, Columbia, MO 65201 Phone: 573-814-6000 Fax: 573-814-6584 | |
Dr. Sameer Bellapravalu, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Hospital Drive Room 313, Psychiatry Dept Dc067.00, Columbia, MO 65212 Phone: 573-884-6136 Fax: 573-884-1070 | |
Trenton Bickel, Internal Medicine Medicare: Medicare Enrolled Practice Location: 1 Hospital Dr # Dc043.00, Columbia, MO 65212 Phone: 573-882-7272 |